Skip to main content
Fig. 7 | Stem Cell Research & Therapy

Fig. 7

From: Gain of CXCR7 function with mesenchymal stem cell therapy ameliorates experimental arthritis via enhancing tissue regeneration and immunomodulation

Fig. 7

MSCs with CXCR7 gain-of-function inhibit the molecular features and severity of arthritis. a, b Levels of TNF-α, IL-1β, IL-6, IL-10, and RANKL in synovial tissues derived from normal rats or rats with collagen-induced arthritis (CIA) receiving vehicle (PBS), control vector-expressing MSC (control MSCs), CXCR7-expressing MSC (CXCR7-MSCs), native MSC (MSCs), vehicle-primed MSC, CCX771-primed MSC, or TC14012-primed MSC treatment on day 28. Data are means ± SD (n=6–8). *P < 0.01 compared with the normal group without CIA. # P < 0.01 compared with the CIA group without any treatment. c Working model of CXCR7 gain-of-function with mesenchymal stem cell therapy ameliorates experimental arthritis

Back to article page